PULIDO, Meldred Gladwin R.

BSN-IV

INDICATION CONTRAINDICA SIDE NURSING

DRUG CLASSIFICATI TION EFFECTS RESPONSIBILI
ON TIES

Vancomycin Serious or severe For oral use only; N/V, abdominal ASSESSMENT
Tricyclic infections due to not systemically pain,
(as HCl) glycopeptide susceptible absorbed. hypokalemia, Assess for
500mg/vial, antibiotic methicillin-resistant Clinically diarrhea, inflammatory
1g/vial; inhibits cell-wall (beta-lactam- significant serum pyrexia, disorders of the
lyophilized pwd biosynthesis. resistant) concentrations flatulence,
intestinal mucosa,
for IV infusion Alters bacterial staphylococci in reported in some urinary tract
renal
after cell-membrane penicillin-allergic patients who have infection,
permeability and taken multiple oral headache, insufficiency,
reconstitution patients; patients
RNA synthesis. doses of therapy peripheral colitis, underlying
and dilution. who cannot receive
or have failed to for active CDAD; edema, back hearing loss,
respond to other significant pain, fatigue, hypersensitivity
Brand name:
systemic nephrotoxicity. to the drug,
drugs, including
absorption may
1. Vancocin penicillins and pregnancy/nursin
occur in some
cephalosporins; and g status, and
HCl patients with
for infections due to possible drug
inflammatory
vancomycin- disorders of the interactions.
2. Vancoled susceptible intestinal mucosa. Perform culture
organisms resistant Monitoring of and susceptibility
to other serum testing.
antimicrobials. concentrations
Staphylococcal
MONITORING
may be
endocarditis, appropriate in Monitor renal
including some instances function, and for
septicemia, and (eg, in patients
ototoxicity,
infections of the with renal
superinfection,
lower respiratory insufficiency
tract, bone, and skin and/or colitis). and other adverse
and skin structure. Nephrotoxicity reactions. Monitor
Streptococcal reported; serum
PULIDO, Meldred Gladwin R.
BSN-IV